Skip to main content
SpringerLink
Log in

Journal Club

  • JOURNAL CLUB
  • Published:
Medizinische Klinik Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Salemi S, Picchanti-Diamanti A, Germano V, et al. Influenca vaccine administration in rheumatoid arthritis patients under treatment with TNF α blockers. Clin Immunol 2010;134:113–20.

    Article  CAS  PubMed  Google Scholar 

Literatur

  1. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482–7.

    Article  PubMed  Google Scholar 

  2. Merrill JT, Neuwelt CM, Fallace DJ, et al. Efficacy and safety of rituximab in moderately to severely active systemic lupus erythematosus. The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab (EXPLORER) trial. Arthritis Rheum 2010;62:222–33.

    Article  PubMed  Google Scholar 

Literatur

  1. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61:1454–61.

    Article  PubMed  Google Scholar 

  2. Marí B, Monteagudo M, Bustamante E, et al. Analysis of temporal artery biopsies in an 18-year period at a community hospital. Eur J Intern Med 2009;20:533–6.

    Article  PubMed  Google Scholar 

Literatur

  1. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rutiximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–92.

    Article  CAS  PubMed  Google Scholar 

  2. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677–84.

    Article  CAS  PubMed  Google Scholar 

  3. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–93.

    Article  CAS  PubMed  Google Scholar 

  4. Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009;27:6101–8.

    Article  CAS  PubMed  Google Scholar 

  5. Dreyling M, Hoster E, Van Hoof A, et al. Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission in mantle cell lymphoma: long term follow up of a randomized trial. Blood 2008;112:285a. abstract 769.

    Google Scholar 

Literatur

  1. Li H, Kantoff PW, Giovannucci E, et al: Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005;65:2498–504.

    Article  CAS  PubMed  Google Scholar 

  2. Chan JM, Oh WK, Xie W, et al. Plasma selenium, manganese superoxide dismutase, and intermediateor high-risk prostate cancer. J Clin Oncol 2009;27:3577–83.

    Article  CAS  PubMed  Google Scholar 

  3. Platz EA, Lippman SM. Selenium, genetic variation, and prostate cancer risk: epidemiology reflects back on selenium and vitamin E cancer prevention trial. J Clin Oncol 2009;27:3569–72.

    Article  CAS  PubMed  Google Scholar 

Literatur

  1. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593–6.

    Article  CAS  PubMed  Google Scholar 

  2. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649–59.

    Article  CAS  PubMed  Google Scholar 

  3. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131–42.

    Article  CAS  PubMed  Google Scholar 

  4. Fuchs C, Meyerhardt JA, Heseltine DL, et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from Intergroup trial CALGB 89803. Proc Am Soc Clin Oncol 2005;23:abstract 3530.

  5. Midgley RSJ, McConkey CC, Langman MJ. VICTOR: a phase III placebo-controlled trial of rofecoxib in colorectal cancer patients following surgical resection. Ann Oncol 2008;19:Suppl 8:viii1,LBA3.

    Google Scholar 

  6. Fuchs C, Marshall J, Mitchell E, et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in mCRC: Updated efficacy date. Proc Am Soc Clin Oncol 2007;25:abstract 4027.

  7. Kerr DJ, Dunn JA, Langman MJ, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007;357:360–9.

    Article  CAS  PubMed  Google Scholar 

  8. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009;374:119–25.

    Article  CAS  PubMed  Google Scholar 

  9. Matsumoto S, Imaeda Y, Umemoto S, et al. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer 2002;86:161–7.

    Article  CAS  PubMed  Google Scholar 

  10. Neugut AI. Aspirin as adjuvant therapy for colorectal cancer. A promising new twist for an old drug. JAMA 2009;302:688–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Journal Club. Med Klin 105, 363–370 (2010). https://doi.org/10.1007/s00063-010-1066-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00063-010-1066-y

Search

Navigation